Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors

H

Hadassah Medical Center

Status and phase

Withdrawn
Phase 2
Phase 1

Conditions

Metastatic Solid Tumors

Treatments

Biological: Tumor Cell Vaccine

Study type

Interventional

Funder types

Other

Identifiers

NCT00148993
100798-HMO-CTIL

Details and patient eligibility

About

The goal of this study is to apply allogeneic tumor cell vaccination for immunotherapy in patients with micro-metastatic disease and/or in patients at high risk disease progression. The present study will use allogeneic tumor cell lines for tumor cell vaccines that share MHC determinants with the patient aiming to overcome possible restriction of antigen presentation.

Enrollment

100 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients with measurable metastatic disease or disease resistant to chemotherapy or with minimal residual disease at high risk to relapse.

Exclusion criteria

Karnofsky less than 60%. Unrelated condition requiring the use of any cytotoxic agents or immunosuppressive agents which may interfere with optimal immune response.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems